InvestorsHub Logo
Followers 7
Posts 346
Boards Moderated 0
Alias Born 05/07/2015

Re: steel8000 post# 27323

Thursday, 02/09/2023 10:23:42 PM

Thursday, February 09, 2023 10:23:42 PM

Post# of 27659
Catlent DID rerun the Anergis allergy study using MYMX virosomes, and DID get compelling results. Anergis had a winner that’s now up for grabs. Catalent has the know-how, finances and facilities to mass-produce vaccines. Seems a viable match. What do others think?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MYMX News